REPUBLIC OF LEBANON MINISTRY OF PUBLIC HEALTH Lebanon Clinical Trials Registry

Helios-B : A Study to Evaluate Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy


13/08/2025 14:18:12

Primary registry identifying number	Protocol number
BCTR2020104517	ALN-TTRSC02-003
MOH registration number	
Study registered at the country of origin	Study registered at the country of origin: Specify
Yes	Study registered at the country of origin. Specify
Type of registration	Type of registration: Justify
Prospective	N/A
Date of registration in national regulatory agency 29/05/2020	
Primary sponsor	Primary sponsor: Country of origin
Alnylam Pharmaceuticals, Inc.	USA
Date of registration in primary registry	Date of registration in national regulatory agency
23/05/2022	29/05/2020
Public title	Acronym
Helios-B : A Study to Evaluate Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy	HELIOS-B
Scientific title	Acronym
Helios-B: A Phase 3, Randomized, Doubleblind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with Cardiomyopathy)	HELIOS-B
Brief summary of the study: English	
This study will evaluate the efficacy and safety of vutrisiran 25 mg administered subcutaneously (SC) once every 3 months (q3M) compared to placebo in patients with ATTR amyloidosis with cardiomyopathy.	
Brief summary of the study: Arabic	
مغم يعطى في شكل حقنة تحت الجلد مرة كل 25ستقوم هذه الدراسة بتقييم فعالية وسلامة فوتريزبران المرضى الذين يعانون من الداء النشواني مع اعتلال عضلة القلب.	اشهر مقارنة مع الدواء الوهمي في3
Health conditions/problem studied: Specify	
Transthyretin Amyloidosis (ATTR) With Cardiomyopathy	
Interventions: Specify	
Arm: Experimental: Vutrisiran 25 mg Participants will receive vutrisiran 25 mg administered subcutaneously (S Assigned Intervention: Drug: Vutrisiran Vutrisiran 25 mg will be administered by SC injection q3M. Other Name: ALN-TTRSC02	SC) once every 3 months (q3M) during the double-blind period.

 \sim

REPUBLIC OF LEBANON MINISTRY OF PUBLIC HEALTH Lebanon Clinical Trials Registry

Placebo Comparator: Placebo Participants will receive placebo during the double-blind period. Assigned Intervention: Drug: Sterile Normal Saline (0.9% NaCl) Sterile normal saline (0.9% NaCl) will be administered by SC injection q3	sm.	
Key inclusion and exclusion criteria: Inclusion criteria		
Inclusion criteria: 1. Has a documented diagnosis of transthyretin (ATTR) amyloidosis with Amyloidosis with cardiomyopathy or wild-type ATTR (wtATTR) amyloido 2. Has medical history of heart failure (HF) with at least 1 prior hospitaliz	sis with cardiomyopathy meeting pr	e-specified diagnostic criteria.
Key inclusion and exclusion criteria: Gender	Key inclusion and exclusion	n criteria: Specify gender
Both		
Key inclusion and exclusion criteria: Age minimum	Key inclusion and exclusion	ı criteria: Age maximum
18	85	
Key inclusion and exclusion criteria: Exclusion criteria		
Exclusion criteria: 1. Has known primary amyloidosis or leptomeningeal amyloidosis 2. Has New York Heart Association (NYHA) Class IV heart failure 3. Has NYHA Class III heart failure AND is at high risk based on pre-spe 4. Has a polyneuropathy disability (PND) Score IIIa, IIIb, or IV at the Scre 5. Has estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m^2 6. Has received prior TTR-lowering treatment 7. Has other non-TTR cardiomyopathy, hypertensive cardiomyopathy, car ischemic heart disease	eening visit	disease, or cardiomyopathy due to
Type of study		
Interventional		
Type of intervention	Type of intervention: Specify	y type
Pharmaceutical	N/A	
Trial scope	Trial scope: Specify scope	
Therapy	N/A	
Study design: Allocation	Study design: Masking	
Randomized controlled trial	Blinded (masking used)	
Study design: Control	Study phase	
Placebo	3	
Study design: Purpose	Study design: Specify purpo	DSe
Treatment	N/A	
Study design: Assignment Parallel	Study design: Specify assig N/A	nment
IMP has market authorization No	IMP has market authorizatio	n: Specify
Name of IMP	Year of authorization	Month of authorization
Vutrisiran (ALN-TTRSC02)		
Type of IMP		
Gene therapy		
Pharmaceutical class		
Synthetic RNA interference (RNAi) therapeutic molecule		





Lebanon Clinical Trials Registry

They pout is indication		
Therapeutic indication Transthyretin Amyloidosis (ATTR) With Cardiomyopathy		
Transinyretin Amyloidosis (ATTR) with Cardiomyopathy		
Therapeutic benefit		
Vutrisiran utilizes RNAi to prevent the synthesis of both wt and mutant TTF source of circulating TTR.		
TTR reduction with vutrisiran will beneficially impact disease progression ir amyloidosis with cardiomyopathy.	a patients with ATTR	
Study model	Study model: Explain model	
N/A	N/A	
Study model: Specify model		
N/A		
Time perspective	Time perspective: Explain time perspective	
N/A	N/A	
Time perspective: Specify perspective		
N/A		
Torget follow up duration	Target follow up duration: Unit	
Target follow-up duration	Target follow-up duration: Unit	
Number of groups/cohorts		
Biospecimen retention	Biospecimen description	
Samples with DNA**	Biological specimens will be collected, may include DNA, RNA, or biochemical metabolite assessments as they relate to disease	
	progression, efficacy or safety. The biospecimen repository will also include residual material	
	from routine samples (safety laboratory samples, PK samples,	
	etc.) that are obtained during the study.	
Target sample size	Actual enrollment target size	
600	Actual enrollment target size	
Date of first enrollment: Type	Date of first enrollment: Date	
Actual	28/05/2021	
Date of study closure: Type	Date of study closure: Date	
Actual	22/09/2021	
Recruitment status	Recruitment status: Specify	
Complete		
Date of completion		
31/07/2021		
IPD sharing statement plan	IPD sharing statement description	
No	n b sharing statement description	

 \sim

REPUBLIC OF LEBANON MINISTRY OF PUBLIC HEALTH Lebanon Clinical Trials Registry

	Not Applicable
Additional data URL	
Admin comments	
Trial status	
Approved	

Secondary Identifying Numbers	
Full name of issuing authority	Secondary identifying number
Food and Drug Administration	NCT04153149
Eudract Number	2019-003153-28

Sources of Monetary or Material Support	
Name	
Alnylam Pharmaceuticals, Inc	

Secondary Sponsors

Name

NA



Contac	t for Public/Scientific Queries					
Contact type	Contact full name	Address	Country	Telephone	Email	Affiliation
Public	Aziz El Zoghbi	MCT-CRO	Lebanon	+961 71 008 269	zog_az@mctcro. com	Director of Country Oversight and Manageme nt Africa, Levant and GCC
Scientific	Alnylam Clinical Trial Information Line Central Contact Person	Not applicable	United States of America	1-877- ALNYLAM	clinicaltrials@aln ylam.com	Alnylam Pharmace uticals, Inc
Scientific	Alnylam Clinical Trial Information Line Central Contact Backup	Not applicable	United States of America	1-877-256- 9526	Not Applicable	Alnylam Pharmace uticals, Inc
Scientific	Jean El Cheikh	American University of Beirut Medical Center	Lebanon	+961 71 407 447	je46@aub.edu.lb	Principal Investigato r

Centers/Hospitals Involved in the Study				
Conter/Hospital name		Principles investigator speciality	Ethical approval	
	American University of Beirut Medical Center	Jean El Cheikh	Hematology/Oncology	Approved

Ethics Review				
Ethics approval obtained	Approval date	Contact name	Contact email	Contact phone
American University of Beirut Medical Center	12/10/2020	Jean El Cheikh	je46@aub.edu.lb	+96171407447

Countries of Recruitment
Name
Lebanon
France
United States of America
Argentina
Australia
Austria
Belgium
Brazil



REPUBLIC OF LEBANON MINISTRY OF PUBLIC HEALTH Lebanon Clinical Trials Registry

ConstaiBugaraConstaiConstainBurnaryIndenRoleRoleRoleCoch RepublicNorwayConstainRole<	Canada
Demark Gemary Ieland Ialy Cach Republic Moxoay Japan Paru Republic of Moldova Poind Parula Robot of Moldova Poindage Poindage Robot of Moldova Poindage Poindage <	Colombia
Gemany Gemany Ieland Ialy Cacch Republic Kenico Norway Japan Paru Republic of Moldova Poland Poland System Indextore Poland System Undextore System System Indextore System Contai Formain	Bulgaria
Ireland Ireland Iay Casch Republic Mexico Noway Japan Peru Republic of Moldova Paland Nording Spain Poland Nording Poland Nording Spain	Denmark
Iay Czeh Republic Mexico Norway Japan Peru Republic of Moldova Poind Neterlands Poingal Spain Noterlands Poingal Spain Contugal Spain Contugal Spain Contugal Spain Contugal Spain Contugal Spain Contugal Spain Contage Spain Contage Spain Contage Co	Germany
Czech Republic Mexico Norway Japan Peru Republic of Moldova Poland Portugal Spain Syden Juited Kingdom Requalization Gradia Syden Linted Kingdom Romania Cortuka Fonda Cortuka Fonda Cortuka Fonda	Ireland
Mexico Norway Japan Peru Republic of Moldova Poland Poltugal Portugal Spain Sydeen United Kingdom Formania Coratia Estonia Finand Formania Coratia Formania Coratia Formania F	Italy
Norway Japan Peru Republic of Moldova Poland Poland Notherlands Portugal Spain Sweden Unted Kingdom Romania Croatia Estonia Finland Fortugal	Czech Republic
Japan Peru Peru Republic of Moldova Poland Poland Netherlands Portugal Portugal Spain Sweden Unted Kingdom Malaysia Taiwan Romania Coctal Estonia	Mexico
Peru Republic of Moldova Poland Poland Netherlands Portugal Spain Sweden United Kingdom Malaysia Taiwan Romania Croatia Estonia Finland Costa Rica	Norway
Republic of Moldova Poland Netherlands Portugal Spain Sweden United Kingdom Malaysia Conatia Romania Estonia Finland Costa Rica	Japan
Poland Netherlands Portugal Spain Sweden United Kingdom Malaysia Taiwan Romania Croatia Estonia Finland Costa Rica	Peru
Netherlands Portugal Spain Sweden United Kingdom Malaysia Taiwan Romania Croatia Estonia Finland Costa Rica	Republic of Moldova
Portugal Spain Sweden United Kingdom Malaysia Taiwan Romania Croatia Estonia Finland Costa Rica	Poland
Spain Sweden United Kingdom Malaysia Taiwan Romania Croatia Estonia Finland Costa Rica	Netherlands
Sweden United Kingdom Malaysia Taiwan Romania Croatia Estonia Estonia Finland	Portugal
United Kingdom Malaysia Taiwan Romania Croatia Estonia Finland Costa Rica	Spain
Malaysia Taiwan Romania Croatia Estonia Finland Costa Rica	Sweden
Taiwan Romania Croatia Estonia Finland Costa Rica	United Kingdom
Romania Croatia Estonia Finland Costa Rica	Malaysia
Croatia Estonia Finland Costa Rica	Taiwan
Estonia Finland Costa Rica	Romania
Finland Costa Rica	Croatia
Costa Rica	Estonia
	Finland
Greece	Costa Rica
	Greece



REPUBLIC OF LEBANON Ministry of Public Health Lebanon Clinical Trials Registry

Hungary
Latvia
Lithuania
Saudi Arabia
Slovakia
Slovenia
Jordan

Health Conditions or Problems Studied			
Condition	Code	Keyword	
Transthyretin Amyloidosis with Cardiomyopathy	Heart failure (I50)	Cardiomyopathy	

Interventions				
Intervention	Description	Keyword		
Experimental: Vutrisiran 25 mg	Participants will receive vutrisiran 25 mg administered subcutaneously (SC) once every 3 months (q3M) during the double-blind period	Vutrisiran, SC, q3M		
Placebo Comparator: Placebo	Participants will receive placebo during the double-blind period.	Placebo		

Primary Outcomes

Name	Time Points	Measure
Composite Endpoint of All-Cause Mortality and Recurrent Cardiovascular (CV) Events (CV Hospitalizations and Urgent Heart Failure [HF] Visits)	[Time Frame: 30-36 months]	All-cause mortality and recurrent CV events (CV hospitalizations and urgent HF visits) will be compared between treatment groups using an Andersen-Gill model.

REPUBLIC OF LEBANON Lebanon Clinical Trials Registry

Key Secondary Outcomes				
Name	Time Points	Measure		
Change from Baseline in 6-Minute Walk Test (6-MWT) at Month 30	[Time Frame: Baseline, Month 30]	Change from baseline in 6-minute walk test (6-MWT)		
Change from Baseline in the Kansas City Cardiomyopathy Questionnaire Overall Summary (KCCQ-OS) at Month 30	[Time Frame: Baseline, Month 30]	Change from baseline in the Kansas City Cardiomyopathy Questionnaire Overall Summary (KCCQ-OS)		
Change from Baseline in Mean Left Ventricular (LV) Wall Thickness by Echocardiographic Assessment at month 30	[Time Frame: Baseline, Month 30]	Change from Baseline in Mean Left Ventricular (LV) Wall Thickness by Echocardiographic Assessment		
Change from Baseline in Global Longitudinal Strain by Echocardiographic Assessment at month 30	[Time Frame: Baseline, Month 30]	Change from Baseline in Global Longitudinal Strain by Echocardiographic Assessment		
Composite Endpoint of All-Cause Mortality and Recurrent Allcause Hospitalizations and Urgent HF Visits	[Time Frame: 30-36 months]	Composite Endpoint of All-Cause Mortality and Recurrent All-cause Hospitalizations and Urgent HF Visits using an Andersen-Gill model.		
All-cause Mortality	[Time Frame: 30-36 months]	All-cause mortality		
Rate of Recurrent CV Events (CV Hospitalizations and Urgent HF Visits)	[Time Frame: 30-36 months]	Recurrent CV hospitalizations		
Change from Baseline in N-terminal prohormone B-type Natriuretic Peptide (NTproBNP) at month 30	[Time Frame: Baseline, Month 30]	Change from Baseline in N-terminal prohormone Btype Natriuretic Peptide (NTproBNP)		

Date of first journal publication of results

Trial Results

Summary results

Study results globally

Date of posting of results summaries

Results URL link

Baseline characteristics

Participant flow

Adverse events

Outcome measures

URL to protocol files

